{"id":20849,"date":"2013-02-01T11:48:46","date_gmt":"2013-02-01T11:48:46","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=20849"},"modified":"2013-02-07T08:07:58","modified_gmt":"2013-02-07T08:07:58","slug":"new-unitaid-grants-focus-on-paediatric-hiv-tb-and-malaria","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/20849","title":{"rendered":"New UNITAID grants focus on paediatric HIV, TB and malaria"},"content":{"rendered":"<p><strong>On 7 December 2012, UNITAID announced several new grants to enable the production of adapted treatments for children in resource limited settings. Among these grants (in USD) are:<\/strong><\/p>\n<p>Up to $17.3 million to the Drugs for Neglected Diseases initiative (DNDi) to make child-adapted paediatric HIV treatments available. This project will help save the lives of some of the 72% of children that require life-saving HIV treatment but don&#8217;t have access.<\/p>\n<p>Up to $16.7 million to the TB Alliance to support the production of appropriate paediatric TB medicine formulations. Currently, a lack of child-adapted TB medicines contributes to high morbidity among children.<\/p>\n<p>Up to $34 million to the Medicines for Malaria Venture (MMV) to accelerate the global adoption of injectable artesunate, the best treatment for the 8 million annual cases of severe malaria, occurring mostly in under-five-year-olds in Sub-Saharan Africa.<\/p>\n<p>In addition to these principle grants, the UNITAID Executive Board approved four market entry grants to manufacturers of point-of-care HIV diagnostic tests in the final stages of development.<\/p>\n<p>A positive decision regarding the request from the Global Fund for an extension of funding of the Affordable Medicines Facility &#8211; malaria (AMFm) is expected in January. Finally, the Executive Board also confirmed its commitment to supporting the WHO Prequalification of Medicines Programme on a multi-year basis.<\/p>\n<p>Source:<\/p>\n<p>UNITAID press release<br \/>\n<a href=\"http:\/\/www.unitaid.eu\/resources\/press-centre\/releases\/1053-eb17-project-release\">http:\/\/www.unitaid.eu\/resources\/press-centre\/releases\/1053-eb17-project-release<\/a><br \/>\n<a href=\"http:\/\/www.dndi.org\/media-centre\/press-releases\">http:\/\/www.dndi.org\/media-centre\/press-releases<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 7 December 2012, UNITAID announced several new grants to enable the production of adapted treatments for children in resource limited settings. Among these grants (in USD) are: Up to $17.3 million to the Drugs for Neglected Diseases initiative (DNDi) &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38,32,37],"tags":[],"class_list":["post-20849","post","type-post","status-publish","format-standard","hentry","category-treatment-access","category-paediatric-care","category-tb-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=20849"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20849\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=20849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=20849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=20849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}